NASDAQ:NVAX 6 November 2025 - 8 May 2026

Novavax surged roughly 13% by Friday afternoon, building on gains after its quarterly results. The vaccine manufacturer topped first-quarter revenue expectations, driven more by licensing and supply agreements than any recovery in COVID-19 vaccine demand. Shares were changing hands at $10.45, with intraday volume topping 8.4 million, market data showed.

Pfizer shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That day, the stock fluctuated between $25.11 and $25.65. ViiV chair David Redfern called the move a way to “simplify the shareholder structure.” Pfizer has also cautioned investors that 2026 could be challenging, as COVID-19 product sales decline, pricing pressures mount, and key patents expire.